February 5, 2026
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Indeterminate
BioSpace
Owner:
Joshua Goodwin